CD8A and myeloid sarcoma: This is consistent with data indicating that in MS patients the levels of circulating CD4+ and CD8+ T-PBLs expressing TCR excision circles (TRECs), traceable molecular markers that identify RTEs, decrease with acute relapses to match those of 30 years older healthy controls [92].